Monday, January 16, 2012

What You Should Know about Denosumab (Prolia) for Increasing Bone Mass during Breast and Prostate Cancer Therapies

In September 2011, the monoclonal antibody RANKL inhibitor denosumab (Prolia) was approved for use in increasing bone mass in patients at high risk for fracture who are receiving androgen deprivation therapy for nonmetastatic prostate cancer or aromatase inhibitor therapy for breast cancer.1 Under the trade name Xgeva, denosumab has an indication for prevention of skeletal-related events in patients with bone metastases from solid tumors at a different dose (120 mg subcutaneously every 4 weeks) than in the current indications. Denosumab (as Prolia) also has a nononcologic indication for treatment of postmenopausal women with osteoporosis at high risk for fracture.


Tony Talebi, MD

1 comment:

  1. Hi there to every body, it’s my first go to see of this web site; this weblog consists of awesome and in fact good stuff for visitors.

    Breast Cancer Treatment Guideline